Telesis Bio Inc Beta
Was ist das Beta von Telesis Bio Inc?
Beta von Telesis Bio Inc ist 0.00
Was ist die Definition von Beta?
BETA gibt an, ob eine Aktie mehr oder weniger schwankungsanfällig ist als der Gesamtmarkt. Ein Beta von weniger als 1 zeigt an, dass die Aktie weniger schwankungsanfällig ist als der Markt, während ein Beta von mehr als 1 anzeigt, dass die Aktie mehr schwankungsanfällig ist. Die Schwankungsanfälligkeit wird als Schwankung des Preises um den Mittelwert gemessen.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Telesis Bio Inc
Was macht Telesis Bio Inc?
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Unternehmen mit beta ähnlich Telesis Bio Inc
- Vision Marine Technologies hat Beta von 0.00
- Ely Gold Royalties hat Beta von 0.00
- Glacier Lake Resources hat Beta von 0.00
- Magnum Mining and Exploration hat Beta von 0.00
- Africa Opportunity Fund hat Beta von 0.00
- Fulcrum Utility Services hat Beta von 0.00
- Telesis Bio Inc hat Beta von 0.00
- Gullewa hat Beta von 0.00
- S.A.L. Steel hat Beta von 0.00
- Andina Acquisition III hat Beta von 0.00
- Andina Acquisition III hat Beta von 0.00
- Brilliant Acquisition hat Beta von 0.00
- Indokem hat Beta von 0.00